Future of Japan Proton Therapy Market Looks Bright, States Renub Research in Its Topical Report Available at MarketPublishers.com
02 Feb 2017 • by Natalie Aster
LONDON – The Japanese proton therapy market was worth just over USD 100 million as of 2016, while the untapped proton therapy market value stood at USD 6 billion in the same year. This indicates that there is considerable mismatch between demand and supply, and the future of the national proton therapy market seems to look very bright.
The number of proton therapy patients in Japan has surged considerably since 2000; in 2016, there were 11 proton therapy centers in existence to treat patients. In particular, proton beam therapy is extremely helpful for childhood cancer. Proton beam therapy in the country is therefore often utilised with cancers that were hard to treat previously only with conventional surgery, radiation therapy or chemotherapy. These comprise carcinoma of the prostate, liver cancer, brain cancer, cervical and optical tumors, and childhood cancers.
Topical research report “Japan Proton Therapy Market, Forecast, Reimbursement Policies & Patients Treated at Centers” created by Renub Research provides an all-round analysis of the rapidly evolving, high-growth proton therapy market on a national level. The report canvasses the actual market and the untapped market. It gives information on the actual and untapped number of patients; includes a list of all existing and future proton therapy centers; casts light on the economics of proton therapy covering reimbursement policies. The report also examines the 3 market players such as IBA, Varian Medical Systems and Elekta, covering their revenues. Furthermore, a detailed analysis of the market drivers and challenges is presented in the study.
Other comprehensive market reports by this publisher can be found in the Renub Research catalogue.